Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

UFL1-Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression

ABSTRACT: Metabolic reprogramming toward enhanced aerobic glycolysis is a defining feature of cancer, yet how the contribution of ubiquitin-like modifications to this process remains poorly understood. Here, we identify the UFMylation E3 ligase UFL1 as a critical suppressor of glycolytic metabolism and colorectal cancer (CRC) progression. Mechanistically, UFL1 directly interacts with the glycolytic enzyme enolase 1 (ENO1) and catalyzes its UFMylation at lysine residues K285 and K420. This modification disrupts ENO1 dimerization, attenuates its enzymatic activity, and consequently suppresses glycolytic flux. Functionally, UFL1-mediated UFMylation restrains tumor growth in vitro and in vivo. Notably, pharmacological enhancement of the UFL1-ENO1 interaction using the FDA-approved antibiotic torezolid significantly potentiates the antitumor efficacy of 5-fluorouracil (5-FU) across multiple preclinical models, including CRC patient-derived organoids and xenografts, without detectable toxicity. Collectively, these findings establish ENO1 as a direct UFMylation substrate, reveal UFMylation as a previously unrecognized regulator of cancer metabolic reprogramming, and highlight the UFL1-ENO1 axis as a promising therapeutic target in colorectal cancer.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Colorectal Cancer

SUBMITTER: Xiuqing Ma

LAB HEAD: Tongzheng Liu

PROVIDER: PXD078510 | Pride | 2026-08-02

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	UFL-1.raw	Raw
	UFL-2.raw	Raw
	UFL-3.raw	Raw
	UFL1.xlsx	Xlsx
	checksum.txt	Txt

Items per page:

1 - 5 of 5

Similar Datasets

UFMylation-Dependent Inhibition of AKT Signaling by PHLDA3 in Lung Adenocarcinoma

Project description:UFMylation, a recently identified ubiquitin-like modification mediated by the E3 ligase UFL1, plays context-specific roles in cancers, but its substrates and functions in lung adenocarcinoma (LUAD) remain poorly defined. Here, we identify the AKT signaling repressor PHLDA3 as a substrate of UFL1 in LUAD. UFMylation of PHLDA3 at Lys51 and Lys106 promotes its membrane localization, thereby blocking AKT membrane recruitment and suppressing downstream signaling. Tumor-associated PHLDA3 mutations F41L, E82G and K106N impair its UFMylation and membrane translocation, resulting in AKT hyperactivation and enhanced tumor growth. In samples from patients with LUAD, UFL1 expression inversely correlates with phosphor-AKT levels. Functionally, the UFL1-PHLDA3 axis inhibits LUAD progression in both cell line-based and patient-derived xenograft models. These findings define a tumor-suppressive UFMylation pathway that modulates AKT activity and provides a mechanistic rationale for targeting UFL1-PHLDA3 signaling in LUAD.

2026-04-08 | PXD074890 | Pride

Targeting the UFL1-AKT Cascade Suppresses Triple-Negative Breast Cancer Progression

Project description:Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease with limited therapeutic options. While UFL1-mediated UFMylation has been implicated in various diseases, its role in TNBC remains unexplored. In this study, we demonstrate that AKT1 directly interacts with UFL1 and undergoes UFMylation at Lys189, Lys276, and Lys297. This modification enhances AKT phosphorylation and activation, promoting tumor growth and chemoresistance in TNBC. In turn, AKT phosphorylates UFL1 at Thr426, establishing a positive feedback loop that sustains high activity of both pro-oncogenic regulators in TNBC. Disrupting the UFL1-AKT interaction using the specific peptide PDAU-TAT significantly inhibits TNBC progression both in vitro and in vivo. Clinically, elevated pT426 UFL1 expression significantly correlates with increased pAKT levels in TNBC specimens. These findings uncover a crucial positive feedback loop between UFL1 and AKT that drives TNBC progression and suggest that targeting the UFL1-AKT axis could offer a promising therapeutic strategy for TNBC and potentially other aggressive cancers characterized by upregulated UFL1 and AKT activation.

2025-11-12 | PXD062168 | Pride

Ufl1 deficiency causes skin pigmentation by u-pregulation of Endothelin-1

Project description:Ufmylation (UFM1 modification) is a newly identified ubiquitin-like modification system involved in numerous cellular processes. However, the regulatory mechanisms and biological functions of this modification remain mostly unknown. We have recently reported that Ufmylation family genes have frequent somatic copy number alterations in human cancer including melanoma, suggesting involvement of Ufmylation in skin function and disease. UFL1 is the only known Ufmylation E3-like ligase. In this study, we generated the skin-specific Ufl1 knockout mice and show that ablation of Ufl1 caused epidermal thickening, pigmentation and shortened life span. RNA-Seq analysis indicated that Ufl1 deletion resulted in upregulation of the genes involved in melanin biosynthesis. Mechanistically, we found that Endothelin-1 (ET-1) is a novel substrate of Ufmylation and this modification regulates ET-1 stability, and thereby deletion of Ufl1 upregulates the expression and secretion of ET-1, which in turn results in up-regulation of genes in melanin biosynthesis and skin pigmentation. Our findings establish the role of Ufl1 in skin pigmentation through Ufmylation modification of ET-1 and provide opportunities for therapeutic intervention of skin diseases.

2025-05-31 | GSE205159 | GEO

UFL1 interactome in human breast cancer cells

Project description:Immunoprecipitation of UFL1 followed by mass spectrometry analysis to identify UFL1 binding partners in human breast cancer cells.

2025-12-08 | PXD062297 | Pride

Identification of dASF/SF2 potential mRNA targets

Project description:Deciphering the role of alternative splicing in developmental processes relies on the identification of key genes whose expression is controlled by splicing regulators throughout growth of a whole organism. Targeting expression of five SR proteins in the developing eye of Drosophila allowed us to show that these splicing factors induce various phenotypic alterations concerning eye organogenesis and viability. Although both dASF/SF2 and B52 caused defects in ommatidia structure, only B52 impairs normal photoreceptor axons projection and neurogenesis in visual ganglia. Consistently, microarray analyses revealed that many of the B52 targets are involved in brain organogenesis and we show that their splicing profile is altered both in B52 loss and gain of function. Conversely, a large proportion of dASF/SF2 targets are involved in eye development. This differential effect argues that SR proteins confer accuracy to developmental gene-expression programs, thus ensuring tissue identity and supporting cell-lineage decisions. Keywords: genetic modification Experiment aimed at identifying dASF/SF2 potential mRNA targets in the Drosophila developing eye Control: GMR X GFP-NLS trangenic larvae The 2 IP- GFP cy3 vs ASF cy5 rep.1 and IP- GFP cy5 vs ASF cy3 rep.1 samples correspond to dye-swap experiments. Two replicates (rep1 and rep2) are included.

2007-09-17 | E-GEOD-5857 | biostudies-arrayexpress

Identification of B52 potential mRNA targets

Project description:Deciphering the role of alternative splicing in developmental processes relies on the identification of key genes whose expression is controlled by splicing regulators throughout growth of a whole organism. Targeting expression of five SR proteins in the developing eye of Drosophila allowed us to show that these splicing factors induce various phenotypic alterations concerning eye organogenesis and viability. Although both dASF/SF2 and B52 caused defects in ommatidia structure, only B52 impairs normal photoreceptor axons projection and neurogenesis in visual ganglia. Consistently, microarray analyses revealed that many of the B52 targets are involved in brain organogenesis and we show that their splicing profile is altered both in B52 loss and gain of function. Conversely, a large proportion of dASF/SF2 targets are involved in eye development. This differential effect argues that SR proteins confer accuracy to developmental gene-expression programs, thus ensuring tissue identity and supporting cell-lineage decisions. Keywords: genetic modification Experiment aimed at identifying B52 potential mRNA targets in the Drosophila developing eye Control: GMR X GFP-NLS trangenic larvae The 2 IP- GFP cy3 vs B52 cy5 rep.1 and IP- GFP cy5 vs B52 cy3 rep.1 samples correspond to dye-swap experiments. Two replicates (rep1 and rep2) are included.

2007-09-17 | E-GEOD-5858 | biostudies-arrayexpress

Identification of UFBP1 interacting proteins

Project description:UFBP1 (UFM1-binding and PCI domain-containing protein 1, also called DDRGK domain-containing protein 1, Dashurin, or C20orf116) is a protein that also participates in the ufmylation conjugating systems besides the E1 ubiquitin-like modifier-activating enzyme 5 (UBA5), the E2, UFM1-conjugating enzyme 1 (UFC1), and the E3, UFM1-protein ligase 1 (UFL1). Although this protein play important roles in the ufmylation, its other biological functions have not been explored. To identify the UFBP1 interacting proteins, we expressed GFP (control sample) and FLAG-UFBP1 (experimental sample) in HEK293T cells and purified UFBP1 and its interacting proteins for MS analysis.

2018-05-08 | PXD009051 | Pride

LC-MS/MS analysis of ribosome UFMylation in vitro

Project description:UFMylation, is a Ubiquitin-like modification occurring on RPL26, a ribosomal subunit, upon ribosome stalling at the ER membrane. This modification is achieved by a pool of enzymes commonly referred to as E1-activating, E2-conjugating and E3-ligase enzymes. The UFM1 E3 ligase comprises of three proteins: UFL1, UFBP1 and CDK5RAP3, referred to as UFM1 Ribosome E3 Ligase (UREL) complex. While UFL1 and UFBP1 are sufficient for E3 ligase activity in vitro, CDK5RAP3 is indispensable for ribosome UFMylation in vivo. In this work, we characterize in vitro UFMylation reaction of purified 60S ribosomes in the presence and absence of CDK5RAP3 using LC-MS/MS. Specifically, we analyse sites of UFMylation, linkage type and quantify monoUFMylation and diUFMylation on RPL26. Interestingly, we find UFMylation to occur on a specific lysine residue, K134, in the presence of UFL1/UFBP1 alone and in complex with CDK5RAP3. In addition, we also provide quantitative information on relative abundances of RPL26 mono- and di-UFMylation under these conditions.

2024-03-22 | PXD046991 | Pride

Mechanism of 60S ribosomal subunit recognition and UFMylation by the UFM1 E3 ligase complex

Project description:During co-translational translocation at the endoplasmic reticulum (ER), ribosomes can stall and become covalently modified with the ubiquitin-like protein UFM1 on the 60S ribosomal subunit RPL26 (uL24). This process, known as UFMylation, is mediated by the UFM1 Ribosome E3 Ligase (UREL) complex, comprised of UFL1, UFBP1, and CDK5RAP3. However, the functional consequences of UFMylation and catalytic mechanisms of UREL are unknown. Here, we present crosslinking-mass spectrometry (XL-MS) data of UREL bound to 60S ribosomes.

2024-03-22 | PXD046990 | Pride

Activation of the JNK–ENO1 Axis Promotes Glycolytic Reprogramming and Progression of Retroperitoneal Leiomyosarcoma

Project description:Retroperitoneal leiomyosarcoma (RPLMS) is a highly aggressive malignancy with limited therapeutic options, and its metabolic underpinnings remain poorly understood. In this study, we identified significant activation of glycolytic pathways in RPLMS through RNA-seq analysis, with enolase 1 (ENO1) markedly upregulated in both tumor tissues and patient-derived cell lines. Functional experiments demonstrated that ENO1 knockdown suppresses proliferation, migration, and glycolytic metabolism in RPLMS cells. Mechanistically, JNK signaling was shown to directly promote ENO1 transcription, thereby driving glycolytic reprogramming. Our findings reveal that the JNK–ENO1 axis plays a critical role in RPLMS progression, suggesting that targeting this pathway may represent a promising therapeutic strategy for this devastating disease.

2026-06-01 | GSE315333 | GEO